Human papillomavirus infection and the risk of cervical cancer in Japan

Journal of Obstetrics and Gynaecology Research

Volumn 39, Issue 1, 2013, Pages 7-17

  Matsumoto, Koji ^a   Yoshikawa, Hiroyuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus; Vaccine

Indexed keywords

HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; ORAL CONTRACEPTIVE AGENT; WART VIRUS VACCINE;

AGE DISTRIBUTION; ARTICLE; CANCER RISK; CARCINOGENICITY; CHLAMYDIASIS; CONTRACEPTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; GENETIC LINKAGE; GENETIC POLYMORPHISM; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 52; IMMUNE RESPONSE; INFECTION RATE; JAPAN; JAPANESE; META ANALYSIS (TOPIC); MIXED INFECTION; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PARITY; PREVALENCE; SMOKING; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VIRUS DETECTION;

CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; JAPAN; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK; UTERINE CERVICAL NEOPLASMS;

EID: 84875702955     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2012.01977.x     Document Type: Article

References (47)

1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
2. Onuki M, Matsumoto K, Satoh T et al. Human papillomavirus infections among Japanese women: Age-related prevalence and type-specific risk for cervical cancer. Cancer Sci 2009; 100: 1312-1316.
3. Dunne EF, Unger ER, Sternberg M et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297: 813-819.
4. Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T. Population-based prevalence, type-And age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 2008; 123: 1864-1870.
5. Herrero R, Castle PE, Schiffman M et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005; 191: 1796-1807.
6. de Sanjosé S, Diaz M, Castellsagué X et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-Analysis. Lancet Infect Dis 2007; 7: 453-459.
7. Statistical Survey Department, Statistics Bureau, Ministry of Internal Affairs and Communications, Japan. 2005 Population Census. [Cited 17 May 2012.] Available from URL: http://www.stat.go.jp/english/data/kokusei/index.htm
8. Miura S, Matsumoto K, Oki A et al. Do we need a different strategy for HPV screening and vaccination in East Asia? Int J Cancer 2006; 119: 2713-2715.
9. Matsumoto K, Oki A, Furuta R et al.; Japan HPV and Cervical Cancer Study Group. Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: A prospective cohort study. Int J Cancer 2011; 128: 2898-2910.
10. Matsumoto K, Hirai Y, Furuta R et al.; for Japan HPV and Cervical Cancer (JHACC) Study Group. Subsequent risks for cervical precancer and cancer in women with lowgrade squamous intraepithelial lesions unconfirmed by colposcopy-directed biopsy: Results from a multicenter, prospective, cohort study. Int J Clin Oncol 2012; 17: 233-239.
11. Muñoz N, Bosch FX, Castellsagué X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-285.
12. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
13. Paavonen J, Naud P, Salmerón J et al.; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-Adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-314.
14. Matsuda T, Marugame T, Kamo KI, Katanoda K, Ajiki W, Sobue T. The Japan Cancer Surveillance Research Group. Cancer Incidence and Incidence Rates in Japan in 2002: Based on Data from 11 Population-based Cancer Registries. Jpn J Clin Oncol 2008; 38: 641-648.
15. Zehbe I, Voglino G, Delius H, Wilander E, Tommasino M. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet 1998; 352: 1441-1442.
16. Matsumoto K, Yoshikawa H, Nakagawa S et al. Enhanced oncogenicity of human papillomavirus type 16 (HPV16) variants in Japanese population. Cancer Lett 2000; 156: 159-165.
17. Yamada T, Manos MM, Peto J et al. Human papillomavirus type 16 sequence variation in cervical cancers: A worldwide perspective. J Virol 1997; 71: 2463-2472.
18. Xin CY, Matsumoto K, Yoshikawa H et al. Analysis of E6 variants of human papillomavirus type 33, 52 and 58 in Japanese women with cervical intraepithelial neoplasia/cervical cancer in relation to their oncogenic potential. Cancer Lett 2001; 170: 19-24.
19. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM. HLA DR-DQ associations with cervical carcinoma show papillomavirus-Type specificity. Nat Genet 1994; 6: 157-162.
20. Matsumoto K, Yasugi T, Nakagawa S et al. Human papillomavirus type 16 E6 variants and HLA class II alleles among Japanese women with cervical cancer. Int J Cancer 2003; 106: 919-922.
21. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002; 296: 1439-1443.
22. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A et al. Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13 541 women with carcinoma of the cervix and 23 017 women without carcinoma of the cervix from23 epidemiological studies. Int J Cancer 2006; 118: 1481-1495.
23. Matsumoto K, Yasugi T, Oki A et al. Are smoking and chlamydial infection risk factors for CIN? Different results after adjustment for HPV DNA and antibodies. Br J Cancer 2003; 89: 831-833.
24. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 2006; 119: 1108-1124.
25. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A et al. Cervical cancer and hormonal contraceptives: Collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370: 1609-1621.
26. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and sexual behavior: Collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiol Biomarkers Prev 2009; 18: 1060-1169.
27. Smith JS, Bosetti C, Munoz N et al. IARC multicentric casecontrol study. Chlamydia trachomatis and invasive cervical cancer: A pooled analysis of the IARC multicentric casecontrol study. Int J Cancer 2004; 111: 431-439.
28. Smith JS, Herrero R, Bosetti C et al.; International Agency for Research on Cancer (IARC) Multicentric Cervical Cancer Study Group. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002; 94: 1604-1613.
29. Magnusson PK, Sparen P, Gyllensten UB. Genetic link to cervical tumours. Nature 1999; 400: 29-30.
30. Hildesheim A, Wang SS. Host and viral genetics and risk of cervical cancer: A review. Virus Res 2002; 89: 229-240.
31. Han R, Breitburd F, Marche PN, Orth G. Linkage of regression and malignant conversion of rabbit viral papillomas to MHC class II genes. Nature 1992; 356: 66-68.
32. Matsumoto K, Oki A, Furuta R et al.; Japan HPV and Cervical Cancer (JHACC) Study Group. Tobacco smoking and regression of low-grade cervical abnormalities. Cancer Sci 2010; 101: 2065-2073.
33. Matsumoto K, Maeda H, Oki A et al.; for Japan HPV and Cervical Cancer (JHACC) Study Group. HLA class II DRB1. 1302 allele protects against progression to cervical intraepithelial neoplasia grade 3: A multicenter prospective cohort study. Int J Gynecol Cancer 2012; 22: 471-478.
34. Stämpfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol 2009; 9: 377-384.
35. Barton SE, Maddox PH, Jenkins D, Edwards R, Cuzick J, Singer A. Effect of cigarette smoking on cervical epithelial immunity: A mechanism for neoplastic change? Lancet 1988; 2: 652-654.
36. Hogewoning CJ, Bleeker MC, van den Brule AJ et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: A randomized clinical trial. Int J Cancer 2003; 107: 811-816.
37. Alloub MI, Barr BB, McLaren KM, Smith IW, Bunney MH, Smart GE. Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. BMJ 1989; 298: 153-156.
38. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997; 337: 1343-1349.
39. Matsumoto K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. Antibodies to human papillomavirus 16, 18, 58, and 6b major capsid proteins among Japanese females. Jpn J Cancer Res 1997; 88: 369-375.
40. Matsumoto K, Yoshikawa H, Yasugi T et al. IgG antibodies to human papillomavirus 16, 52, 58, and 6 L1 capsids: Casecontrol study of cervical intraepithelial neoplasia in Japan. J Med Virol 2003; 69: 441-446.
41. Stanley M. Prophylactic human papillomavirus vaccines:Will they do their job? J Intern Med 2010; 267: 251-259.
42. Ochi H, Matsumoto K, Kondo K et al., for Japan HPV and Cervical Cancer (JHACC) Study Group. Do neutralizing antibody responses generated by human papillomavirus infections favor a better outcome of low-grade cervical lesions? J Med Virol 2012; 84: 1128-1134.
43. Kirnbauer R, Chandrachud LM, O'Neil BW et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996; 219: 37-44.
44. Hildesheim A, Herrero R, Wacholder S et al.; Costa Rican HPV Vaccine Trial Group. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial. JAMA 2007; 298: 743-753.
45. Matsumoto K, Yoshikawa H, Yasugi T et al. Balance of IgG subclasses toward human papillomavirus type 16 (HPV16) L1-capsids is a possible predictor for the regression of HPV16-positive cervical intraepithelial neoplasia. Biochem Biophys Res Commun 1999; 258: 128-131.
46. Trimble CL, Frazer IH. Development of therapeutic HPV vaccines. Lancet Oncol 2009; 10: 975-980.
47. Matsumoto K, Leggatt GR, Zhong J et al. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors. J Natl Cancer Inst 2004; 96: 1611-1619.